FDA Approval of Obesity treatments, Qnexa
Manufacturers of obesity treatments may need to study the heart risks of their therapies before regulators weigh approval, the Food and Drug Administration said in a report Monday.
Three California companies are competing to bring the first weight-loss pill to market in 13 years: Vivus Inc., Orexigen Therapeutics Inc. and Arena Pharmaceuticals Inc.
The FDA is set to decide on Vivus’s drug Qnexa by April 17. Arena’s medication faces an advisory panel May 10.
An advisory panel will hold a hearing on the drugs in starting Wednesday. The FDA doesn’t have to follow the panel’s recommendations.